Best Options Strategy for MRNA
Looking for the best options strategy for Moderna (MRNA)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live MRNA option chain right now, and a simple map from your view on MRNA to the strategy that fits it. Model any of them in the calculator before you trade.
About MRNA
Moderna (MRNA) is a major company in mRNA vaccines and therapeutics. Options traders on MRNA tend to watch vaccine demand, trial data and earnings, since these can drive large moves in the share price.
MRNA for options traders
Moderna is one of the most volatility-rich names in the biotech universe. Its implied volatility (IV) is structurally elevated because the company's revenue and pipeline outlook can swing dramatically on clinical trial readouts, regulatory decisions, partnership announcements, and shifts in public health policy. Earnings reports carry an added dimension: guidance revisions can reprice the stock sharply in either direction, and the options market prices that uncertainty into premiums well before the event.
Options liquidity is reasonably good for a mid-cap biotech, with active volume across near-term strikes and sufficient open interest to support multi-leg strategies. Long straddles and strangles are popular around binary catalysts — traders pay for the move without committing to direction. Between catalysts, when IV compresses, premium sellers turn to short straddles, iron condors, or covered calls to harvest inflated time value. Given the potential for gap-style moves, position sizing and defined-risk structures are especially important here.
Today's top-scoring strategy for MRNA
Our engine ranks defined-risk strategies on the live MRNA chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $85 | $1.55 |
| Sell | 1× | PUT | $105 | $4.00 |
| Sell | 1× | CALL | $120 | $17.33 |
| Buy | 1× | CALL | $120 | $17.33 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $191 | $239 | $219 | $181 | $129 | $66 |
| $184 | $235 | $208 | $162 | $103 | $35 |
| $176 | $228 | $193 | $138 | $71 | −$1 |
| $168 | $218 | $172 | $108 | $33 | −$44 |
| $161 | $202 | $143 | $68 | −$13 | −$94 |
| $153 | $177 | $104 | $19 | −$68 | −$152 |
| $145 | $139 | $51 | −$43 | −$134 | −$219 |
| $138 | $82 | −$20 | −$119 | −$212 | −$295 |
| $130 | $1 | −$111 | −$213 | −$303 | −$383 |
| $122 | −$113 | −$228 | −$325 | −$409 | −$482 |
| $115 | −$266 | −$371 | −$458 | −$530 | −$592 |
Live scan from 2026-08-19 · quotes delayed ~15 minutes
Historical backtest: how a Iron Butterfly on MRNA would have performed
We approximated a Iron Butterfly on MRNA, entered repeatedly over the past year (93 historical entries, each held to expiration) with Black-Scholes-modelled entry premiums. Here is how that would have played out on real MRNA price history — an educational backtest, not a prediction of future returns.
Approximate: entry premiums are modelled with Black-Scholes from trailing realised volatility, held to expiration and settled against the real historical close. Real fills, implied volatility and slippage differ — treat it as directional context, not exact returns.
Implied volatility
MRNA is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 121% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on MRNA currently price in about 121% implied volatility, versus roughly 275% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
MRNA's IV Rank is 100/100: implied volatility sits 100% of the way between its 19-day low (66%) and high (121%), and is above 90% of recorded days. Premium is historically rich, which favours net-credit strategies like credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$52.28 (±34%) in MRNA by 2026-09-18 — a range of roughly $101 to $205. Strikes inside that band hold most of the premium and see most of the action.
MRNA options chain highlights: open interest, volume and skew
The live MRNA options chain shows a put/call open-interest ratio of 1.24 (balanced), with at-the-money implied volatility near 107.2%.
Snapshot of open interest, volume and implied volatility for the nearest scanned expiration — context, not a trading signal.
MRNA insider trading activity (SEC Form 4)
Open-market insider transactions at MRNA over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Bancel Stephane | Sell | 187,044 | $11.0M | 2026-08-05 |
| Bancel Stephane | Sell | 39,891 | $2.3M | 2026-08-05 |
| Bancel Stephane | Sell | 124,838 | $7.1M | 2026-08-05 |
| Bancel Stephane | Sell | 147,473 | $8.3M | 2026-08-05 |
| Hoge Stephen | Sell | 53,336 | $3.6M | 2026-07-15 |
| Klinger Shannon Thyme | Sell | 3,471 | $174K | 2026-06-04 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Earnings & IV crush
MRNA's next earnings report is due around November 5, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $25.7B
- Beta (vs market)
- 0.90
- 52-week range
- $22.28–$85.60 (100% up the range)
- Short interest
- 15.2% of float · 7.2 days to cover
With 15.2% of MRNA's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for MRNA
Start with your outlook on MRNA, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while MRNA stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open MRNA in the free calculator →
Frequently asked questions
What is the best options strategy for MRNA?
It depends on your outlook. Bullish traders often use a long call or bull call spread on MRNA; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are MRNA options liquid enough to trade?
Moderna (MRNA) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade MRNA options?
Buying a single MRNA call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade MRNA or any security. Do your own research.
What does Moderna do?
Moderna (MRNA) operates in the Biotechnology industry. The "About Moderna" section above gives a fuller picture of what the company does and how it earns money.
Does Moderna pay a dividend?
We don't show a confirmed dividend yield for Moderna here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does Moderna next report earnings?
Moderna's next earnings are expected around November 5, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Price trend
Tickers related to MRNA
Comparing MRNA with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 325 Binney Street, Cambridge, MA, 02142, United States
- Industry
- Biotechnology
- Employees
- 4,700
- CEO
- Mr. Stéphane Bancel M.B.A.
- Phone
- 617 714 6500
- Website
- www.modernatx.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.